Paul Matteis
Biotech analyst, Stifel
aka Paul Matisse
“So if you used to assume that Replimune or Agios had a 10 or 20% probability of success, I don't know, I'd probably put that well above 50% for both of those two drugs right now.”
“It's just the patients on tafamidis at baseline that there's like no benefit means no benefit. And here's the strangest one, like no benefit on CV biomarkers. So like there's not even a biological effect.”
“Alnylam stock yesterday opened up about 17% based on the idea that, okay, now they're going to own this silencer market.”
“This sort of specialty, rare endo space has kind of quietly become pretty hot and it feels like it's sort of the next little niche space to get hot and become its own little sub vertical.”
“The more interesting play are the brain shuttle approaches like Denali and Arrowhead, which can be given IV, and maybe a much lower efficacy bar given ease of use.”
Paul Matteis
One-line summary: Stifel biotech analyst; covers Vertex, Neurocrine, Ionis, Alnylam, Biogen; densest causal contributor on Biotech Hangout.
What they're known for
Brief factual context — fill in.
Why they matter to stock-market
Why this person's claims are tracked here — fill in.
Said
Speaker-attributed claims extracted from diarized sources. Each bullet mirrors one entry in quotes: frontmatter — keep them in sync.
-
On fda-rare-disease-regulatory-right-shift:
"So if you used to assume that Replimune or Agios had a 10 or 20% probability of success, I don't know, I'd probably put that well above 50% for both of those two drugs right now." — 2026-07-10-podcast-biotech-hangout-episode-188-july-10-2026 (2026-07-10)
-
On eplontersen-failure-to-alnylam-silencer-consolidation:
"It's just the patients on tafamidis at baseline that there's like no benefit means no benefit. And here's the strangest one, like no benefit on CV biomarkers. So like there's not even a biological effect." — 2026-07-10-podcast-biotech-hangout-episode-188-july-10-2026 (2026-07-10)
-
On eplontersen-failure-to-alnylam-silencer-consolidation:
"Alnylam stock yesterday opened up about 17% based on the idea that, okay, now they're going to own this silencer market." — 2026-07-10-podcast-biotech-hangout-episode-188-july-10-2026 (2026-07-10)
-
On rare-endo-vertical-to-neurocrine-vertex:
"This sort of specialty, rare endo space has kind of quietly become pretty hot and it feels like it's sort of the next little niche space to get hot and become its own little sub vertical." — 2026-07-10-podcast-biotech-hangout-episode-188-july-10-2026 (2026-07-10)
-
On biogen-tau-failure-to-brain-shuttle-rerate:
"The more interesting play are the brain shuttle approaches like Denali and Arrowhead, which can be given IV, and maybe a much lower efficacy bar given ease of use." — 2026-07-10-podcast-biotech-hangout-episode-188-july-10-2026 (2026-07-10)
Sources
Related
Cross-links — fill in.